Drug Repurposing Campaigns for Human Cytomegalovirus Identify a Natural Compound Targeting the Immediate-Early 2 (IE2) Protein: A Comment on “The Natural Flavonoid Compound Deguelin Inhibits HCMV Lytic Replication within Fibroblasts”
Funding
Conflicts of Interest
References
- Mocarski, E.S.; Shenk, T.; Griffiths, P.D.; Pass, R.F. Cytomegaloviruses. In Fields Virology, 6th ed.; Knipe, D.M., Howley, P.M., Eds.; Wolters Kluwer Lippincott Williams & Wilkins: Philadelphia, PA, USA, 2013; pp. 1960–2014. [Google Scholar]
- Griffiths, P.; Baraniak, I.; Reeves, M. The pathogenesis of human cytomegalovirus. J. Pathol. 2015, 235, 288–297. [Google Scholar] [CrossRef] [PubMed]
- Britt, W.J. Maternal immunity and the natural history of congenital human cytomegalovirus infection. Viruses 2018, 10, 405. [Google Scholar] [CrossRef] [PubMed]
- Fu, T.M.; An, Z.; Wang, D. Progress on pursuit of human cytomegalovirus vaccines for prevention of congenital infection and disease. Vaccine 2014, 32, 2525–2533. [Google Scholar] [CrossRef] [PubMed]
- Britt, W.J.; Prichard, M.N. New therapies for human cytomegalovirus infections. Antiviral. Res. 2018, 159, 153–174. [Google Scholar] [CrossRef] [PubMed]
- Mercorelli, B.; Palù, G.; Loregian, A. Drug repurposing for viral infectious diseases: How far are we? Trends Microbiol. 2018, 26, 865–876. [Google Scholar] [CrossRef] [PubMed]
- Gardner, T.J.; Cohen, T.; Redmann, V.; Lau, Z.; Felsenfeld, D.; Tortorella, D. Development of a high-content screen for the identification of inhibitors directed against the early steps of the cytomegalovirus infectious cycle. Antiviral Res. 2015, 113, 49–61. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Mercorelli, B.; Luganini, A.; Nannetti, G.; Tabarrini, O.; Palù, G.; Gribaudo, G.; Loregian, A. Drug repurposing approach identifies inhibitors of the prototypic viral transcription factor IE2 that block human cytomegalovirus replication. Cell Chem. Biol. 2016, 23, 340–351. [Google Scholar] [CrossRef] [PubMed]
- Nukui, M.; O’Connor, C.M.; Murphy, E.A. The natural flavonoid compound deguelin inhibits HCMV lytic replication within fibroblasts. Viruses 2018, 10, 614. [Google Scholar] [CrossRef] [PubMed]
- Luganini, A.; Caposio, P.; Mondini, M.; Landolfo, S.; Gribaudo, G. New cell-based indicator assays for the detection of human cytomegalovirus infection and screening of inhibitors of viral immediate-early 2 protein activity. J. Appl. Microbiol. 2008, 105, 1791–1801. [Google Scholar] [CrossRef] [PubMed]
- Wang, Y.; Ma, W.; Zheng, W. Deguelin, a novel anti-tumorigenic agent targeting apoptosis, cell cycle arrest and anti-angiogenesis for cancer chemoprevention. Mol. Clin. Oncol. 2013, 1, 215–219. [Google Scholar] [CrossRef] [PubMed]
- Smith, I.L.; Taskintuna, I.; Rahhal, F.M.; Powell, H.C.; Ai, E.; Mueller, A.J.; Spector, S.A.; Freeman, W.R. Clinical failure of CMV retinitis with intravitreal cidofovir is associated with antiviral resistance. Arch. Ophthalmol. 1998, 116, 178–185. [Google Scholar] [CrossRef] [PubMed]
- Mercorelli, B.; Luganini, A.; Celegato, M.; Palù, G.; Gribaudo, G.; Loregian, A. Repurposing the clinically approved calcium antagonist manidipine dihydrochloride as a new early inhibitor of human cytomegalovirus targeting the Immediate-Early 2 (IE2) protein. Antiviral Res. 2018, 150, 130–136. [Google Scholar] [CrossRef] [PubMed]
- Luganini, A.; Mercorelli, B.; Messa, L.; Palù, G.; Gribaudo, G.; Loregian, A. The isoquinoline alkaloid berberine inhibits human cytomegalovirus replication by interfering with the viral Immediate Early-2 (IE2) protein transactivating activity. Antiviral Res. under revision.
- Baba, Y.; Fujii, M.; Maeda, T.; Suzuki, A.; Yuzawa, S.; Kato, Y. Deguelin induces apoptosis by targeting both EGFR-AKT and IGF1R-AKT pathways in head and neck squamous cell cancer cell lines. Biomed. Res. Int. 2015, 2015, 657179. [Google Scholar] [CrossRef] [PubMed]
- Dell’Eva, R.; Ambrosini, C.; Minghelli, S.; Noonan, D.M.; Albini, A.; Ferrari, N. The Akt inhibitor deguelin, is an angiopreventive agent also acting on the NF-kappaB pathway. Carcinogenesis 2007, 28, 404–413. [Google Scholar] [CrossRef] [PubMed]
- Kudchodkar, S.B.; Yu, Y.; Maguire, T.G.; Alwine, J.C. Human cytomegalovirus infection induces rapamycin-insensitive phosphorylation of downstream effectors of mTOR kinase. J. Virol. 2004, 78, 11030–11039. [Google Scholar] [CrossRef] [PubMed]
- Caposio, P.; Luganini, A.; Hahn, G.; Landolfo, S.; Gribaudo, G. Activation of the virus-induced IKK/NF-kB signalling axis is critical for the replication of human cytomegalovirus in quiescent cells. Cell Microbiol. 2007, 9, 2040–2054. [Google Scholar] [CrossRef] [PubMed]
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Mercorelli, B.; Luganini, A.; Palù, G.; Gribaudo, G.; Loregian, A. Drug Repurposing Campaigns for Human Cytomegalovirus Identify a Natural Compound Targeting the Immediate-Early 2 (IE2) Protein: A Comment on “The Natural Flavonoid Compound Deguelin Inhibits HCMV Lytic Replication within Fibroblasts”. Viruses 2019, 11, 117. https://doi.org/10.3390/v11020117
Mercorelli B, Luganini A, Palù G, Gribaudo G, Loregian A. Drug Repurposing Campaigns for Human Cytomegalovirus Identify a Natural Compound Targeting the Immediate-Early 2 (IE2) Protein: A Comment on “The Natural Flavonoid Compound Deguelin Inhibits HCMV Lytic Replication within Fibroblasts”. Viruses. 2019; 11(2):117. https://doi.org/10.3390/v11020117
Chicago/Turabian StyleMercorelli, Beatrice, Anna Luganini, Giorgio Palù, Giorgio Gribaudo, and Arianna Loregian. 2019. "Drug Repurposing Campaigns for Human Cytomegalovirus Identify a Natural Compound Targeting the Immediate-Early 2 (IE2) Protein: A Comment on “The Natural Flavonoid Compound Deguelin Inhibits HCMV Lytic Replication within Fibroblasts”" Viruses 11, no. 2: 117. https://doi.org/10.3390/v11020117